Primary Hypercholesterolemia Active Not Recruiting Phase 2 Trials for Inclisiran (DB14901)

Also known as: Type IIa hyperlipidaemia / Dyslipidemia (Fredrickson Type Ⅱa) / Type IIa Hypercholesterolemia / Primary Hypercholesterolaemia / Familial Hypercholesterolaemia / Familial Hypercholesterolemia / Hypercholesterolemia, Familial / Type IIa hyperlipoproteinemia / Hyperlipoproteinemia Type IIa / Fredrickson Type IIa hyperlipoproteinemia / Type IIa hyperlipoproteinaemia / Pure hypercholesterolemia / Fredrickson Type IIa hyperlipoproteinaemia / Fredrickson Type IIa hyperlipidemia / Fredrickson Type IIa hyperlipidaemia / Fredrickson Type IIa lipidemia / Fredrickson Type IIa lipidaemia / Type IIa hyperlipidemia / Type II lipidemia / Type II lipidaemia / Hyperlipoproteinemia Type II / Type II hyperlipoproteinaemia / Type II hyperlipoproteinemia / Fredrickson Type II hyperlipidaemia / Fredrickson Type II lipidemia / Fredrickson Type II hyperlipidemia / Type II hyperlipidaemia / Fredrickson Type II lipidaemia / Type II hyperlipidemia

IndicationStatusPhase
DBCOND0033454 (Primary Hypercholesterolemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03060577An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High CholesterolTreatment